Super-Selective Intraarterial Infusion of Cetuximab (Erbitux) With or Without Radiation Therapy for the Treatment of Unresectable Recurrent Squamous Cell Carcinoma of the Head and Neck

NCT02438995 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

11

Enrollment

OTHER

Sponsor class

Stopped Low enrollment

Conditions

Carcinoma, Squamous Cell
Carcinoma, Squamous Cell of Head and Neck

Interventions

DRUG: Intraarterial Cetxuimab (Erbitux)

Sponsor

Northwell Health